The overall objective of this proposal is to support the participation of the city of Hope National Medical Center (COH) in the investigational clinical trials of the Southwest Oncology Group (SWOG). The COH, an NCI- designated Cancer Research Center, has provided strong support for the clinical research activities of SWOG during the past four years. SWOG members at COH or its affiliates have provided leadership to the group in the area of bone marrow transplantation and the treatment of hematological malignancies through: the administrative chairmanship of the bone marrow transplantation committee, the coordination of several SWOG studies in this area, and the development of pilot data from COH that has formed the basis for new SWOG transplantation trials. In addition to its strengths in bone marrow transplantation, the pharmacological expertise of SWOG members at COH has been utilized in novel biochemical modulation trials for patients with breast and colorectal cancer; and the institution's leadership role in the development of novel immunotherapies has enhanced the activities of the developmental biologics and melanoma committees in which COH investigators currently play an important part. Finally, COH strengths in cytogenetics, the molecular virology of human papillomaviruses, and hematopathology have led to new laboratory-based clinical studies in the cytogenetics, gynecology, and leukemia biology working groups. In this regard, a pilot program which has established a human solid tumor cytogenetics laboratory at COH has contributed directly to the ability of SWOG to propose a similar, groupwide facility. Over the current funding cycle, the COH has met the accrual goal it established in its previous application by enrolling an average of 92 patients/year from 1989-91 with a high rate of eligibility and evaluability; over 90% of the patients accrued by COH to SWOG studies have come directly from patients treated at COH, putting COH in the upper third of SWOG members with respect to institutional patient accrual. Furthermore, because of the charitable endowment of the COH, a substantial proportion of patients enrolled on SWOG trials are from minority populations and lack any form of third-party medical insurance. Based upon an enlarging network of COH-affiliated CGOP institutions, on the availability of the largest bone marrow transplantation facility in California (30 beds for hematological disease, 9 beds for solid tumors), on the presence of a multidisciplinary team of physicians in Pathology, Surgery, and Radiation Oncology as well as Medical Oncology and Hematology, and on strong scientific leadership in the areas of clinical pharmacology, molecular virology, transplantation and cytogenetics, an increase in patient accrual to SWOG trials at COH to the level of 120-130 patients per year can be predicted over the coming funding cycle.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope National Medical Center
United States
Zip Code
Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641

Showing the most recent 10 out of 153 publications